Soligenix, Inc.
SNGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000812796
No open-market purchases or sales by Soligenix, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $369.6K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Soligenix, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 11 | 7 | −4 |
| Shares | 100.4K | 66.1K | −34.3K (−34.2%) |
| Value | $259.1K | $262.4K | +$3.27K (+1.3%) |
New holders (2)
Institutions that held Soligenix, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stephens Inc | 46,262 | $183.7K | 0.00% |
| Geode Capital Management, LLC | 18,365 | $72.9K | 0.00% |
Sold out (6)
Institutions that held Soligenix, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Armistice Capital, LLC | 80,000 | $206.4K |
| Old National Bancorp | 10,000 | $25.8K |
| UBS Group AG | 6,231 | $16.1K |
| Wells Fargo & Company | 1 | $3 |
| FMR LLC | 1 | $3 |
| Trust Co of Vermont | 1 | $3 |